PeriRx is the premier developer of a breakthrough, non-invasive, oral diagnostic technology that will help healthcare professionals and their patients improve their health.
The Company has developed a saliva test that uses proven bio-chemistry analytics at high sensitivity and specificity to enable early disease risk detection. Healthcare experts agree that early detection of treatable diseases can enhance patient wellness while reducing cost of healthcare.
The first commercial product PeriRx introduced will be for oral cancer, a disease that impacts 40,000 patients per year. Licensed technology from UCLA to clinically address, early disease detection and to aid in accurate diagnosis of oral, lung, breast cancer as well as Sjögren’s Syndrome, diabetes type I and II and Alzheimer’s disease will be commercialized by PeriRx.